InnoCan Pharma Corporation

CNSX:INNO Stok Raporu

Piyasa değeri: CA$65.7m

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

InnoCan Pharma Yönetim

Yönetim kriter kontrolleri 3/4

InnoCan Pharma's CEO is Iris Bincovich, appointed in Jan 2018, has a tenure of 6.75 years. total yearly compensation is $337.00K, comprised of 79.5% salary and 20.5% bonuses, including company stock and options. directly owns 1.81% of the company’s shares, worth CA$1.19M. The average tenure of the management team and the board of directors is 5.2 years and 4.9 years respectively.

Anahtar bilgiler

Iris Bincovich

İcra Kurulu Başkanı

US$337.0k

Toplam tazminat

CEO maaş yüzdesi79.5%
CEO görev süresi6.8yrs
CEO sahipliği1.8%
Yönetim ortalama görev süresi5.2yrs
Yönetim Kurulu ortalama görev süresi4.9yrs

Son yönetim güncellemeleri

It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

May 04
It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

Recent updates

We're Hopeful That InnoCan Pharma (CSE:INNO) Will Use Its Cash Wisely

Aug 09
We're Hopeful That InnoCan Pharma (CSE:INNO) Will Use Its Cash Wisely

It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

May 04
It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

Dec 06
Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

We Think InnoCan Pharma (CSE:INNO) Can Afford To Drive Business Growth

Aug 15
We Think InnoCan Pharma (CSE:INNO) Can Afford To Drive Business Growth

Companies Like InnoCan Pharma (CSE:INNO) Are In A Position To Invest In Growth

Apr 19
Companies Like InnoCan Pharma (CSE:INNO) Are In A Position To Invest In Growth

Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

Jul 20
Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

We Think InnoCan Pharma (CSE:INNO) Needs To Drive Business Growth Carefully

Apr 05
We Think InnoCan Pharma (CSE:INNO) Needs To Drive Business Growth Carefully

CEO Tazminat Analizi

Iris Bincovich'un ücretlendirmesi InnoCan Pharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$4m

Mar 31 2024n/an/a

-US$5m

Dec 31 2023US$337kUS$268k

-US$5m

Sep 30 2023n/an/a

-US$5m

Jun 30 2023n/an/a

-US$3m

Mar 31 2023n/an/a

-US$4m

Dec 31 2022US$401kUS$291k

-US$4m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

-US$7m

Mar 31 2022n/an/a

-US$6m

Dec 31 2021US$645kUS$300k

-US$10m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$14m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$361kUS$223k

-US$10m

Sep 30 2020n/an/a

-US$3m

Jun 30 2020n/an/a

-US$5m

Mar 31 2020n/an/a

-US$3m

Dec 31 2019US$384kUS$219k

-US$3m

Sep 30 2019n/an/a

-US$6m

Dec 31 2018US$165kUS$54k

-US$2m

Tazminat ve Piyasa: Iris's total compensation ($USD337.00K) is above average for companies of similar size in the Canadian market ($USD176.73K).

Tazminat ve Kazançlar: Iris's compensation has been consistent with company performance over the past year.

CEO

Iris Bincovich (54 yo)

6.8yrs

Görev süresi

US$337,000

Tazminat

Mrs. Iris Bincovich has been Member of Advisory Board at Ayurcann Holdings Corp. since May 2021. Mrs. Bincovich has been the Chief Executive Officer at InnoCan Pharma Corporation since January 2018 and has...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Ron Mayron
Executive Chairman5.1yrsUS$136.00k2.3%
$ 1.5m
Iris Bincovich
CEO & Director6.8yrsUS$337.00k1.81%
$ 1.2m
Nelson Halpern
Chief Financial Officer5.7yrsUS$64.00k0.11%
$ 69.8k
Roni Kamhi
COO & CEO of BI Sky Global and Director2.2yrsUS$230.00k0.16%
$ 102.2k
Eyal Flom
Director & Company Secretary4.8yrsVeri yok0.89%
$ 587.2k
Yoram Drucker
Founder & Executive VP of Business Developmentno dataUS$173.00kVeri yok

5.2yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: INNO's management team is seasoned and experienced (5.2 years average tenure).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Ron Mayron
Executive Chairman5.1yrsUS$136.00k2.3%
$ 1.5m
Iris Bincovich
CEO & Director5.1yrsUS$337.00k1.81%
$ 1.2m
Roni Kamhi
COO & CEO of BI Sky Global and Directorless than a yearUS$230.00k0.16%
$ 102.2k
Eyal Flom
Director & Company Secretary5.1yrsVeri yok0.89%
$ 587.2k
Izhar Shay
Member of Advisory Committee3.3yrsVeri yokVeri yok
Peter Bloch
Independent Director4.8yrsVeri yok0.025%
$ 16.6k
Joseph Pergolizzi
Member of Scientific Advisory Board1.1yrsVeri yokVeri yok
Yechezkel Barenholz
Scientific Advisorno dataVeri yokVeri yok
Joshua Lintern
Independent Director5.1yrsVeri yok0.071%
$ 46.8k
Ralph C. Bossino
Director5.1yrsVeri yok0.11%
$ 72.1k
Josef Geldwert
Scientific Advisorno dataVeri yokVeri yok
Mitchell Kline
Member of Scientific Advisory Committee3.6yrsVeri yokVeri yok

4.9yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: INNO's board of directors are considered experienced (4.9 years average tenure).